by Solural Pharma | Jun 1, 2017 | News
Oncoral Pharma ApS initiates first human dosing on Herlev Hospital using a proprietary oral Irinotecan tablet product developed by Solural Pharma in combination therapy with oral capicitabine tablet in adult patients with solid tumors.
by Solural Pharma | Jun 29, 2016 | News
Solural Pharma ApS enters into an exclusive license agreement with Dyna Therapeutics Co., Ltd, Korea to develop and commercialize SOL-804 for treatment of metastatic castration resistant prostate cancer. SOL-804 is based on the proprietary Solural Lymphatic Targeting...
by Solural Pharma | Jul 16, 2015 | News
Oncoral Pharma ApS initiates first human dosing on Herlev Hospital using a proprietary oral irinotecan product developed by Solural Pharma
by Solural Pharma | Apr 22, 2015 | News
Solural Pharma ApS receives Certificate of GMP Compliance of a Manufacturer issued by the Danish Health and Medicines Authority
by Solural Pharma | Feb 17, 2015 | News
The Danish Innovation Fund has granted Solural Pharma 1.5 mio DKK for together with Contera Pharma ApS (part of Bukwang Pharmaceuticals Co Ltd) , Dr. Sandra Klein, the University of Greifswald and Erweka Gmbh, to develop a new innovative product for the treatment of...
